How to source winlevi? Not generica Product 4/25/2026
The conversation is about sourcing Winlevi (clascoterone) for personal use in the EU. The user is specifically looking for a non-generic version.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity Winlevi Clascoterone- resultssss
The conversation is about using Winlevi Clascoterone cream for hair loss. The user is considering adding it to their routine, which includes a topical hair growth serum, and is seeking feedback on its effectiveness.
community Winlevi (clascoterone 1%) anyone trying it
Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.
community Winlevi (clascoterone) for hairloss?
Winlevi (clascoterone), a DHT blocker, is being considered for hair loss treatment, though it's primarily an acne medication. Users discuss its potential effectiveness and note it may only work for a short time.
community EMA is re-examining Winlevi (clascoterone at lower concentration)
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
community does anybody have winlevi clascoterone yet?
The conversation is about hair loss treatments, specifically discussing the use of Minoxidil, Finasteride, and RU58841. A user inquired about the availability of Winlevi (clascoterone) for hair loss.
community Women complaining of bad effects from Winlevi (Clascoterone 1%)
Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.
Related Research
6 / 6 resultsresearch Clascoterone: First Approval
This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.
research Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
This review discusses the clinical trials of clascoterone 1% cream for acne vulgaris and reports no new results; the authors highlight its novel role as a topical antiandrogen.
research BRIDGING THE GAP IN ACNE MANAGEMENT: A NARRATIVE REVIEW OF CURRENT THERAPIES AND THE EMERGENCE OF CLASCOTERONE
This source describes clascoterone, a new topical treatment for acne vulgaris that blocks androgen receptors to reduce sebaceous gland activity and inflammation, offering a lower risk of systemic side effects compared to oral treatments.
research Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist
This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.
research Clascoterone in the Treatment of Acne Vulgaris: A Narrative Review
This review summarizes existing evidence about clascoterone cream, which significantly reduces acne lesions with a favorable safety profile, but reports no new clinical results and suggests further research for other potential applications.
research Journal of Pigmentary Disorders
This presentation highlighted future directions in acne care, emphasizing the roles of topical and oral antibiotics, as well as skin microbiome studies. It also described how clascoterone targets androgen receptors in hair follicles and sebaceous glands to reduce sebum production.